Dallas, TX (PRWEB) June 08, 2011
Natural Dental Implants (NDI), Inc. the Dallas-based subsidiary of Natural Dental Implants AG, headquartered in Berlin, Germany, today announced the closing of a follow-on financing of 1,000,000 EUR to be used for commercializing the Company’s patented REPLICATE™ Non-surgical Tooth Replacement System. A new investor to the Company, BB BIOTECH VENTURES, advised by the Swiss-based Bellevue Group led the round followed by IBB Beteiligungsgesellschaft mbH, based in Berlin, Germany. IBB Beteiligungsgesellschaft mbH participated already in the Series A financing with High-Tech Gruenderfonds GmbH & Co. KG.
“With our firm’s long-standing investment history in the dental implant industry, we see NDI’s technology for making patient customized dental implants as a major innovation in this field that has significant potential,” said Dr. Klaus Breiner, Managing Partner of BB BIOTECH VENTURES. “The non-surgical approach opens the market to many more providers and offers a patient-friendly alternative to current methods.”
“Having experienced partners with strong financial resources as well as in-depth industry knowledge and relationships provides a tremendous advantage to a company like ours,” added Ruedger Rubbert, CEO of NDI AG. “Both BB BIOTECH VENTURES and IBB Beteiligungsgesellschaft have excellent reputations and are committed to supporting our long-term success.”
NDI expects the REPLICATE™ System to be available in European market during the second half of 2011.
About Natural Dental Implants AG
Natural Dental Implants AG, headquartered in Berlin, Germany, with a U.S. subsidiary based in Dallas, Texas, was founded in 2006 to develop the intellectual property behind the REPLICATE™ Nonsurgical Tooth Replacement System. Research and development operations began in 2009. The company expects to enter the market in the second half of 2011. Visit http://www.replicatetooth.com to learn more.
About BB BIOTECH VENTURES
BB BIOTECH VENTURES (http://www.bbbiotechventures.com) is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Group, which has operations in Curaçao, Boston, USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated team of investment advisors and an advisory board. In addition, it is supported by the Group’s healthcare investment experts, and an extensive network of specialists and advisors. Bellevue Group is a publicly listed Swiss investment bank and is, with BB BIOTECH, BB MEDTECH, and BB BIOTECH VENTURES, amongst the largest financial investors in the health care segment worldwide. Over the last two decades, the Group has raised and invested more than USD 500 million in venture capital.